Pt-141 + Oxytocin For Sale
Investigating dual-pathway neuroendocrine signaling requires reference-grade peptides with verifiable chemical purity and lot consistency. PX1 Research supplies USA-manufactured PT-141 and Oxytocin research compounds for in vitro assays and preclinical animal models. Every batch undergoes third-party ISO 17025 analytical verification, ensuring precise concentration and structural integrity for critical laboratory applications.
Quick answer
Investigating dual-pathway neuroendocrine signaling requires reference-grade peptides with verifiable chemical purity and lot consistency. PX1 Research supplies USA-manufactured PT-141 and Oxytocin research compounds for in vitro assays and preclinical animal models. Every batch undergoes third-party ISO 17025 analytical verification, ensuring precise concentration and structural integrity for critical laboratory applications.
Key takeaways
- Researchers seeking [PT-141](/research-peptides/pt-141) + [oxytocin](/research-peptides/oxytocin) for sale can procure analytical-grade reference material directly from PX1 Research for laboratory use only.
- The co-investigation of [PT-141](/research-peptides/pt-141) and [Oxytocin](/research-peptides/oxytocin) represents an active area of study in central nervous system (CNS) pharmacology, specifically surrounding neuroendocrine signaling and central arousal networks.
- [PT-141](/research-peptides/pt-141) (Bremelanotide) was engineered to bypass peripheral vascular pathways by targeting central melanocortin receptors located within the central nervous system.
- [Oxytocin](/research-peptides/oxytocin) operates as both a hypothalamic hormone and a central neurotransmitter, exercising broad regulatory control over neuroendocrine reflexes and complex social behaviors.
Direct Answer: Sourcing PT-141 + Oxytocin For Laboratory Research
Researchers seeking PT-141 + oxytocin for sale can procure analytical-grade reference material directly from PX1 Research for laboratory use only. Formulated for in vitro assays and preclinical non-human models, PX1 provides high-purity PT-141 (Bremelanotide) and Oxytocin compounds verified via third-party RP-HPLC and Mass Spectrometry, complete with lot-specific Certificates of Analysis (COAs) and endotoxin testing.
When purchasing combined or co-administered peptide reagents, lab investigators must prioritize structural identity and chemical stability. Impurities or degraded nonapeptide fragments can skew receptor binding assays, alter intracellular cyclic AMP (cAMP) expression, or invalidate baseline behavioral metrics in preclinical models. PX1 Research ensures all research-grade compounds are synthesized in domestic, GMP-compliant facilities and shipped directly from California and Arizona facilities under optimized temperature controls.
Molecular Dynamics: Melanocortin Agonism & Neuropeptide Pathways
The co-investigation of PT-141 and Oxytocin represents an active area of study in central nervous system (CNS) pharmacology, specifically surrounding neuroendocrine signaling and central arousal networks. Rather than acting via peripheral vascular mechanisms, both molecules target central hypothalamic regions that regulate autonomic and behavioral responses.
PT-141, a synthetic cyclic peptide derivative of alpha-melanocyte-stimulating hormone (α-MSH), functions primarily as a selective agonist at melanocortin receptors, displaying high binding affinity for MC3R and MC4R. Concurrently, Oxytocin is a cyclic nonapeptide synthesized in the paraventricular and supraoptic nuclei of the hypothalamus, acting via the G-protein coupled oxytocin receptor (OXTR) to modulate social bonding, stress responses, and downstream monoaminergic neurotransmission. Investigating these dual targets allows researchers to map potential crosstalk between melanocortinergic signaling and central oxytocinergic pathways in our comprehensive research peptide library.
Pharmacological Mechanisms of PT-141 (Bremelanotide)
PT-141 (Bremelanotide) was engineered to bypass peripheral vascular pathways by targeting central melanocortin receptors located within the central nervous system. Preclinical studies suggest that activation of central MC4R within the medial preoptic area (mPOA) and paraventricular nucleus (PVN) of the hypothalamus triggers downstream release of dopamine and norepinephrine.
In contrast to legacy compounds, PT-141 exhibits minimal affinity for the MC1R subtype when compared to precursor peptides, significantly reducing melanogenic activity while preserving central nervous system potency. Laboratory investigators utilize PT-141 research compounds to analyze receptor internalisation kinetics, second-messenger cAMP accumulation, and neuronal activation maps using c-Fos expression in rodent brain slices.
Oxytocin Signaling in Central Neuroendocrine Circuits
Oxytocin operates as both a hypothalamic hormone and a central neurotransmitter, exercising broad regulatory control over neuroendocrine reflexes and complex social behaviors. Upon binding to its cognate G-protein-coupled receptor (OXTR), oxytocin activates the Gq/11 signaling cascade, elevating intracellular calcium levels via phospholipase C-beta (PLCβ) activation.
In preclinical rodent and non-human primate models, central administration of oxytocin modulates amygdala reactivity, attenuates corticosterone responses to stress, and enhances mesolimbic dopaminergic signaling. Researchers interested in neuroendocrine research often utilize high-purity oxytocin compounds to study synaptic plasticity, neuropeptide transport across the blood-brain barrier, and the modulation of reward circuit dynamics.
Comparative Analysis: PT-141, Melanotan II, and Oxytocin
Understanding the distinct pharmacological profiles of melanocortin agonists and neuropeptides is critical for experimental design. While PT-141 acts selectively on MC3R and MC4R to trigger central signaling, its structural predecessor Melanotan II exhibits potent, unselective agonism across MC1R, MC3R, MC4R, and MC5R, making MT-II prone to driving cutaneous pigmentation alongside central effects. Conversely, Oxytocin operates on a completely distinct Gq-coupled receptor family (OXTR), lacking affinity for melanocortin receptors altogether. Combining or co-evaluating these distinct ligands enables laboratories to evaluate potential convergent downstream pathways—such as hypothalamic dopamine release—without overlapping primary receptor cross-reactivity.
To explore the comparative receptor binding profiles and receptor selectivity of these compounds in detail, investigators can review our dedicated guide on melanocortin receptor mechanisms, which details affinity kinetics and signaling cascades across preclinical models.
Preclinical Evidence: Dual-Pathway Synergies in CNS Research
In vitro and animal studies indicate that the hypothalamic melanocortin and oxytocinergic systems interact cooperatively to regulate central autonomic functions. Preclinical studies suggest that MC4R activation within the paraventricular nucleus stimulates oxytocinergic neurons, inducing local oxytocin release into regional brain structures including the ventral tegmental area (VTA) and nucleus accumbens.
In rodent behavioral models, co-administration of melanocortin agonists and oxytocin receptor ligands has demonstrated additive effects on appetitive and pro-social behaviors. Researchers mapping these pathways utilize dual-agent protocols to determine whether oxytocin receptor antagonists can block melanocortin-induced signaling, thereby clarifying the precise hierarchical structure of central neuroendocrine cascades. Advanced insights into these neurochemical pathways are documented within the PX1 Research Hub.
Supplier Quality Verification: Analytics, COAs, and Purity Standards
When procuring PT-141 + oxytocin for sale, analytical verification is paramount. Impure peptide samples containing truncated sequences, residual TFA (trifluoroacetic acid), or bacterial endotoxins can induce non-specific cell toxicity, artifactual receptor desensitization, or inflammatory responses in animal models. PX1 Research enforces strict quality assurance protocols for every lot synthesized.
Each batch is tested in an independent, ISO 17025-accredited laboratory using High-Performance Liquid Chromatography (RP-HPLC) to confirm chemical purity exceeding 99%, alongside Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm precise molecular mass. Furthermore, every lot undergoes Chromogenic LAL testing to guarantee endotoxin levels remain strictly under <0.01 EU/mg. Publicly accessible, lot-specific COAs provide complete transparency for institutional procurement and lab compliance.
Laboratory Handling, Reconstitution, and Storage Protocols
Proper handling and storage are essential to maintain the structural integrity of lyophylized nonapeptides and cyclic peptides. Upon receipt, lyophilized PT-141 and Oxytocin vials should be stored at -20°C or -80°C in a desiccated environment to prevent moisture accumulation and enzymatic degradation.
For reconstitution in laboratory settings, researchers should use sterile, bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear mechanical agitation during solubilization; gentle swirling is recommended to prevent peptide aggregation or tertiary structure disruption. Once reconstituted, liquid aliquots should be stored at 2°C to 8°C for short-term assays or flash-frozen in single-use aliquots at -80°C to eliminate repeated freeze-thaw cycles. Comprehensive reconstitution guidelines are available through our wholesale and institutional support portal.
Institutional Sourcing and Bulk Research Procurement
PX1 Research supports university laboratories, biotechnology organizations, and independent research institutions with dependable supply chains and volume pricing. Orders placed Monday through Friday ship same-day from our primary distribution hubs in California and Arizona, utilizing temperature-controlled packaging to protect peptide stability during transit.
Whether purchasing standalone reference standards or exploring custom co-formulations for high-throughput screening, PX1 Research offers flexible account options for verified research entities. Detailed documentation, safety data sheets (SDS), and batch-level traceability are standard with every institutional order.
Frequently Asked Questions
What is the primary mechanism of action for PT-141 in research models?
PT-141 (Bremelanotide) acts as a selective agonist at central melanocortin receptors, predominantly MC3R and MC4R. In preclinical models, activation of these receptors in the medial preoptic area and paraventricular nucleus of the hypothalamus triggers central dopaminergic and noradrenergic pathways involved in central arousal and autonomic signaling.
How does Oxytocin differ from PT-141 in receptor targeting?
While PT-141 targets Gs-coupled melanocortin receptors (MC3R/MC4R), Oxytocin targets the Gq-coupled oxytocin receptor (OXTR). Oxytocin acts primarily as a hypothalamic neuropeptide modulating social bonding, stress responses, and central reward pathways through intracellular calcium mobilization.
Why are PT-141 and Oxytocin studied together in preclinical assays?
Preclinical literature indicates that hypothalamic MC4R activation can directly stimulate oxytocinergic neurons in the paraventricular nucleus. Studying both compounds together allows researchers to analyze potential neuroendocrine synergies and cross-talk between central melanocortin signaling and downstream oxytocin release.
What purity standards does PX1 Research guarantee for PT-141 and Oxytocin?
PX1 Research guarantees peptide purity exceeding 99% for all research compounds. Every lot is verified via third-party Reverse-Phase HPLC for purity and ESI-Mass Spectrometry for sequence verification, with detailed lot-specific COAs provided with every purchase.
Are PX1 Research compounds tested for endotoxins?
Yes. Every batch undergoes Chromogenic LAL (Limulus Amebocyte Lysate) testing to verify that bacterial endotoxin levels remain below strict limits (<0.01 EU/mg), ensuring compatibility with sensitive cell cultures and in vivo animal models.
How should reconstituted PT-141 and Oxytocin solutions be stored in the lab?
Reconstituted solutions should be aliquoted into single-use microcentrifuge tubes and stored at -80°C for long-term stability. Short-term working solutions can be kept at 2°C to 8°C for up to 7–14 days. Avoid repeated freeze-thaw cycles to prevent peptide degradation.
What solvent is recommended for reconstituting PT-141 + Oxytocin research peptides?
Reconstitution is typically performed using sterile bacteriostatic water or standard laboratory phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of the specific in vitro or in vivo experimental protocol.
Are PT-141 and Oxytocin from PX1 Research suitable for human consumption?
No. All compounds sold by PX1 Research are strictly engineered and designated for laboratory research use only. They are not for human or animal therapeutic, diagnostic, or clinical use under any circumstances.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.